このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
CytomX Therapeutics マネジメント
マネジメント 基準チェック /34
CytomX Therapeutics'の CEO はSean McCarthyで、 Aug2011年に任命され、 の在任期間は 12.83年です。 の年間総報酬は$ 2.61Mで、 25%給与と75%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.68%を直接所有しており、その価値は$ 725.97K 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と4.4年です。
主要情報
Sean McCarthy
最高経営責任者
US$2.6m
報酬総額
| CEO給与比率 | 25.0% |
| CEO在任期間 | 12.8yrs |
| CEOの所有権 | 0.7% |
| 経営陣の平均在職期間 | 3.2yrs |
| 取締役会の平均在任期間 | 4.4yrs |
経営陣の近況
Recent updates
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
Jun 15
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now
May 09CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
May 02CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Checking In On CytomX Therapeutics
Jun 13Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being
Jun 10CytomX EPS beats by $0.06, misses on revenue
May 06Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%
Mar 25CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$3m | US$652k | -US$569k |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$42m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$3m | US$623k | -US$99m |
| Sep 30 2022 | n/a | n/a | -US$149m |
| Jun 30 2022 | n/a | n/a | -US$143m |
| Mar 31 2022 | n/a | n/a | -US$132m |
| Dec 31 2021 | US$4m | US$616k | -US$116m |
| Sep 30 2021 | n/a | n/a | -US$72m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$3m | US$595k | -US$65m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$76m |
| Dec 31 2019 | US$4m | US$575k | -US$133m |
| Sep 30 2019 | n/a | n/a | -US$99m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$83m |
| Dec 31 2018 | US$5m | US$550k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$52m |
| Jun 30 2018 | n/a | n/a | -US$39m |
| Mar 31 2018 | n/a | n/a | -US$50m |
| Dec 31 2017 | US$3m | US$500k | -US$43m |
報酬と市場: Seanの 総報酬 ($USD 2.61M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。
報酬と収益: Seanの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Sean McCarthy (57 yo)
12.8yrs
在職期間
US$2,611,138
報酬
Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since August 2021. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been it...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman & CEO | 12.8yrs | US$2.61m | 0.68% $ 726.0k | |
| Senior VP & Chief Scientific Officer | 1.4yrs | US$1.21m | 0.076% $ 81.4k | |
| Senior VP | 3.2yrs | US$1.05m | 0.068% $ 72.5k | |
| Senior VP of Finance & Accounting | 2.8yrs | データなし | 0.033% $ 34.8k | |
| Senior VP | 6.1yrs | US$1.21m | 0.083% $ 88.8k | |
| Senior VP & Chief Human Resources Officer | no data | データなし | データなし | |
| Senior Vice President of Intellectual Property | 5.3yrs | データなし | データなし | |
| Chief Medical Officer | less than a year | データなし | データなし | |
| Senior Vice President of Quality & Product Manufacturing | 1.4yrs | データなし | データなし | |
| Special Advisor to Chief Executive Officer | no data | US$273.54k | データなし |
3.2yrs
平均在職期間
55.5yo
平均年齢
経験豊富な経営陣: CTMXの経営陣は 経験豊富 であると考えられます ( 3.2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman & CEO | 12.8yrs | US$2.61m | 0.68% $ 726.0k | |
| Independent Director | 5.1yrs | US$75.12k | 0.0066% $ 7.0k | |
| Member of Scientific Advisory Board | 4.4yrs | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 3.5yrs | US$78.62k | 0% $ 0 | |
| Independent Director | 5.5yrs | US$77.12k | 0% $ 0 | |
| Lead Independent Director | 8.8yrs | US$105.12k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$80.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.5yrs | US$8.03m | データなし | |
| Independent Director | 2.8yrs | US$69.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.4yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 1.4yrs | データなし | データなし |
4.4yrs
平均在職期間
61yo
平均年齢
経験豊富なボード: CTMXの 取締役会 は 経験豊富 であると考えられます ( 4.4年の平均在任期間)。